- Previous Close
13.94 - Open
13.97 - Bid 13.68 x 100
- Ask 13.83 x 100
- Day's Range
13.69 - 14.15 - 52 Week Range
13.01 - 22.40 - Volume
95,819 - Avg. Volume
151,282 - Market Cap (intraday)
378.933M - Beta (5Y Monthly) 2.00
- PE Ratio (TTM)
-- - EPS (TTM)
-1.77 - Earnings Date Oct 30, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
20.37
ZimVie Inc., together with its subsidiaries, develops, manufactures, and markets a portfolio of products and solutions designed to support dental tooth replacement and restoration procedures worldwide. It operates through The Dental Segment. The company offers dental implant systems; biomaterials; prosthetic and abutment products, surgical instrumentation, and kits; and patient-specific restorative solutions, such as abutments, bars, implant bridges, and hybrid restorations under the BellaTek brand name. It provides bone grafts, barrier membranes, and collagen wound care products; virtual treatment planning services, guided surgery solutions, CAD/CAM workflow systems, and intra-oral scanners; and Implant Concierge, a web-based treatment planning and surgery guide service. The company sells its products to oral surgeons, dental specialists, general dentists, dental laboratories, and other dental organizations, including DSOs, as well as educational, medical, and governmental entities, hospitals, and surgery centers through direct sales representatives, agents, and distributors. ZimVie Inc. was incorporated in 2021 and is headquartered in Palm Beach Gardens, Florida with additional facilities around the globe.
www.zimvie.comRecent News: ZIMV
View MorePerformance Overview: ZIMV
Trailing total returns as of 12/13/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ZIMV
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ZIMV
View MoreValuation Measures
Market Cap
378.93M
Enterprise Value
546.32M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.83
Price/Book (mrq)
0.93
Enterprise Value/Revenue
1.21
Enterprise Value/EBITDA
16.97
Financial Highlights
Profitability and Income Statement
Profit Margin
-77.31%
Return on Assets (ttm)
-0.50%
Return on Equity (ttm)
-8.55%
Revenue (ttm)
451.29M
Net Income Avi to Common (ttm)
-47.73M
Diluted EPS (ttm)
-1.77
Balance Sheet and Cash Flow
Total Cash (mrq)
66.81M
Total Debt/Equity (mrq)
57.59%
Levered Free Cash Flow (ttm)
162.3M